

ARISTOTLE: a phase 3, randomized, double-blind trial of patients with nonvalvular atrial fibrillation (NVAF)^{1,2}

INDICATION

ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. **SELECTED IMPORTANT SAFETY INFORMATION**

WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA

(A) Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant. (B) Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

- use of indwelling epidural catheters
- a history of traumatic or repeated epidural or spinal punctures
- a history of spinal deformity or spinal surgery


• optimal timing between the administration of ELIQUIS and neuraxial procedures is not known Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated.

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Granger CB, Alexander JH, McMurray JJ, et al; for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.

• concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants

Continue








CLINICAL TRIALS: ARISTOTLE

ARISTOTLE was a pivotal, phase 3, randomized clinical trial of >18,000 patients with NVAF^{1-3*}

Primary objective

Determine whether ELIQUIS was effective (noninferior to warfarin) in reducing the risk of stroke (ischemic or hemorrhagic) or systemic embolism (SE)



*Key inclusion criteria: NVAF and ≥1 additional risk factors for stroke, including prior stroke or transient ischemic attack, prior SE, aged ≥75 years, arterial hypertension requiring treatment, diabetes mellitus, heart failure (New York Heart Association Class 2 or higher), or LVEF $\leq 40\%$.

Key exclusion criteria: atrial fibrillation due to a reversible cause, moderate or severe mitral stenosis, conditions other than atrial fibrillation that required anticoagulation (eg, a prosthetic heart valve), stroke within the previous 7 days, a need for aspirin at a dose of >165 mg a day or for both aspirin and clopidogrel, and severe renal insufficiency (serum creatinine level of >2.5 mg/dL or calculated creatinine clearance of <25 mL/min).

INR=international normalized ratio; LVEF=left ventricular ejection fraction; VKA=vitamin K antagonist. ⁺A dose of 2.5 mg twice daily was assigned to patients with at least 2 of the following characteristics: aged ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. *Intracranial bleeding included intracerebral, intraventricular, subdural, and subarachnoid bleeding. Any type of hemorrhagic stroke was adjudicated and counted as intracranial major bleeding.

SELECTED IMPORTANT SAFETY INFORMATION **CONTRAINDICATIONS**

- Active pathological bleeding
- Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions)

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Granger CB, Alexander JH, McMurray JJ, et al; for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. 3. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(suppl 11):981-992. https://www.nejm.org/doi/suppl/10.1056/NEJMoa1107039/suppl_file/nejmoa1107039_protocol.pdf. Accessed November 10, 2021.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.

Bleeding outcomes

Superiority of ELIQUIS to warfarin was also examined for: **Primary efficacy endpoint:** stroke/SE **Primary safety endpoint:** major bleeding **Key secondary efficacy outcome:** all-cause mortality

Major bleeding was defined as clinically overt bleeding **accompanied by ≥1 of the following:** a decrease in hemoglobin of ≥ 2 g/dL; transfusion of ≥ 2 units of packed red blood cells; bleeding that occurred in at least one of the following critical sites: intracranial,^{*} intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal; and fatal bleeding.

Baseline characteristics: the 2 treatment groups were well balanced, including age, stroke risk as measured by a CHADS, score, and prior VKA experience.


BASELINE CHARACTERISTICS

CHADS, SCORE





CLINICAL TRIALS: ARISTOTLE



*Key inclu arterial hy

Key exclu anticoagul severe renal

*This is not a complete list of baseline characteristics. Additional baseline characteristics were evaluated in this trial. ⁺Scale from 0 to 6 to estimate stroke risk; higher scores predict greater risk. References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Granger CB, Alexander JH, McMurray JJ, et al; for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.


INR=international normalized ratio; LVEF=left ventricular ejection fraction; VKA=vitamin K antagonist. ⁺A dose of 2.5 mg twice daily was assigned to patients with at least 2 of the following characteristics: aged ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. *Intracranial bleeding included intracerebral, intraventricular, subdural, and subarachnoid bleeding. Any type of hemorrhagic stroke was adjudicated and counted as intracranial major bleeding.

SELECTED IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS


- Active pathological bleeding
- Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions)

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Granger CB, Alexander JH, McMurray JJ, et al; for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. 3. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(suppl 11):981-992. https://www.nejm.org/doi/suppl/10.1056/NEJMoa1107039/suppl_file/nejmoa1107039_protocol.pdf. Accessed November 10, 2021.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.



IS 0		farin 0081
	7	' 0
1	2.1:	±1.1
1=3100	34%	n=3083
า=3262	36%	n=3254
า=2758	30%	n=2744
1748=1	20%	n=1790
า=5208	57%	n=5193




Mean percentage of time in therapeutic range (INR 2.0-3.0) was 62% for patients treated with warfarin.



ARISTOTLE w7

Primary objective

Determine whethe risk of stroke (isch



CHADS, score¹

A CHADS, score was used to estimate stroke risk in patients with atrial fibrillation. It was calculated by adding up the applicable points below, with higher scores representing a greater risk for stroke.

	CHADS ₂ score	
	Condition	Points
С	Congestive heart failure	1
н	Hypertension	1
Α	Age (≥75)	1
D	Diabetes mellitus	1
S	History of stroke or transient ischemic attack	2
	Possible total:	6 points

*Key inclusion criter arterial hypertension

Key exclusion criteri

anticoagulation (eg, a severe renal insufficie

INR=international normalized ⁺A dose of 2.5 mg twice daily wa**Reference: 1.** Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-2870.

*Intracranial bleeding included intracerebral, intraventricular, subdural, and subarachnoid bleeding. Any type of hemorrhagic stroke was adjudicated and counted as intracranial major bleeding.

SELECTED IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS

- Active pathological bleeding
- Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions)

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Granger CB, Alexander JH, McMurray JJ, et al; for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. 3. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(suppl 11):981-992. https://www.nejm.org/doi/suppl/10.1056/NEJMoa1107039/suppl_file/nejmoa1107039_protocol.pdf. Accessed November 10, 2021.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.



nortality

rt bleeding

ardial,

ars,

at required

xamined for: ase in hemoglobin d blood cells; llowing critical

nt syndrome,


ups were well d by a CHADS,



and clopidogrel, and



In patients with NVAF, **ONLY ELIQUIS** demonstrated superiority in **BOTH** stroke/SE and major bleeding vs warfarin¹



SECONDARY EFFICACY ENDPOINT +

ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.

- Purely ischemic strokes occurred with similar rates on both drugs¹
- $(1.41\%/\text{year vs } 0.92\%/\text{year, HR}=1.54 [95\% CI: 0.96, 2.45]; P=0.07)^1$

ARR=absolute risk reduction; CI=confidence interval; HR=hazard ratio; RRR=relative risk reduction. *Bleeding events were counted during treatment or within 2 days of stopping study treatment (on-treatment period). Bleeding events within each subcategory were counted once per subject, but subjects may have contributed events to multiple endpoints.

SELECTED IMPORTANT SAFETY INFORMATION: WARNINGS AND PRECAUTIONS

transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.

Reference: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.



• Superiority to warfarin was primarily attributable to a reduction in hemorrhagic stroke and ischemic strokes with hemorrhagic conversion compared with warfarin.


• In another clinical trial (AVERROES), ELIQUIS was associated with an increase in major bleeding compared with aspirin that was not statistically significant

• The most common reason for treatment discontinuation in both ARISTOTLE and AVERROES was bleeding-related adverse reactions; in ARISTOTLE, this occurred in 1.7% and 2.5% of patients treated with ELIQUIS and warfarin, respectively, and in AVERROES, in 1.5% and 1.3% on ELIQUIS and aspirin, respectively¹

• Increased Risk of Thrombotic Events after Premature Discontinuation: Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the



In patients with NV **ONLY ELIQUIS**



- Superiority to warfar Purely ischemic strol
- In another clinical tri (1.41%/year vs 0.92%)
- The most common re in 1.7% and 2.5% of


ARR=absolute risk reduction; *Bleeding events were counter but subjects may have contrib

SELECTED IMPORTA

 Increased Risk of Th the absence of adequ transition from ELIQU bleeding or completion.

ELIQUIS[®] (apixaban) is the only anticoagulant that demonstrated a superior reduction in the risk of death vs warfarin^{1,2}

Significant risk reduction in all-cause mortality



- warfarin (1.14%/year vs 1.22%/year, HR=0.93 [95% Cl: 0.77, 1.13])²

SELECTED IMPORTANT SAFETY INFORMATION: WARNINGS AND PRECAUTIONS


or completion of a course of therapy, consider coverage with another anticoagulant.

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Granger CB, Alexander JH, McMurray JJ, et al; for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11): 981-992. **3.** Data on file: APIX 025. Bristol-Myers Squibb Company, Princeton, NJ.

Reference: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.





ELIQUIS N=9120

warfarin N=9081

Secondary efficacy endpoint

• Cardiovascular deaths (1.80%/year vs 2.02%/year, HR=0.89 [95% Cl: 0.76, 1.04]), particularly stroke deaths (0.42% vs 0.72%), were the greatest contributors to the reduction in all-cause mortality vs warfarin^{2,3}

• The incidence of nonvascular mortality was similar in patients taking ELIQUIS to that in patients taking

• Increased Risk of Thrombotic Events after Premature Discontinuation: Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding

tively

rin¹

וts*

irin

, in ٦e



E, this occurred

ly significant

npared with warfarin.


CLINICAL TRIALS: ARISTOTLE



In patients with NVAF,

ELIQUIS demonstrated lower rates in select bleeding outcomes vs warfarin^{1-3*}

Results



ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.

- HR=1.54 [95% CI: 0.96, 2.45]; P=0.07)¹
- patients treated with ELIQUIS and warfarin, respectively, and in AVERROES, in 1.5% and 1.3% of patients treated with ELIQUIS and aspirin, respectively¹

Components of ICH and fatal bleeding

- (n=15/9088) vs 0.34%/year (n=51/9052), HR=0.29 (95% CI: 0.16, 0.51)¹
- 0.04%/year (n=6/9088) vs 0.05%/yr (n=7/9052), HR=0.84 (95% CI: 0.28, 2.15)¹

CRNM was defined as clinically overt bleeding that did not satisfy the criteria for major bleeding and that led to^{4,5}:

1. Hospital admission; 2. Physician-guided medical or surgical treatment for bleeding; or 3. A change in antithrombotic therapy CRNM=clinically relevant nonmajor; ICH=intracranial hemorrhage.

*Bleeding events were counted during treatment or within 2 days of stopping study treatment (on-treatment period). Bleeding events in each subcategory were counted once per subject, but subjects may have contributed events to multiple endpoints.

[†]On-treatment analysis based on the safety population, compared with intent-to-treat analysis presented in the efficacy population.

SELECTED IMPORTANT SAFETY INFORMATION: WARNINGS AND PRECAUTIONS (cont'd)

• Bleeding Risk: ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.

- heparin, thrombolytic agents, SSRIs, SNRIs, and NSAIDs.
- with active pathological hemorrhage.

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Data on file: APIX 060. Bristol-Myers Squibb Company, Princeton, NJ. 3. Data on file: APIX 063. Bristol-Myers Squibb Company, Princeton, NJ. 4. Granger CB, Alexander JH, McMurray JJ, et al; for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. 5. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(suppl 11):981-992. https://www.nejm.org/doi/suppl/10.1056/NEJMoa1107039/suppl_file/nejmoa1107039_protocol.pdf. Accessed November 10, 2021.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.

Bleeding outcomes

• In another clinical trial (AVERROES), ELIQUIS was associated with an increase in major bleeding compared with aspirin that was not statistically significant (1.41%/year vs 0.92%/year,

• The most common reason for treatment discontinuation in both ARISTOTLE and AVERROES was bleeding-related adverse reactions; in ARISTOTLE, this occurred in 1.7% and 2.5% of

• There were significantly fewer ICH events vs warfarin. Hemorrhagic stroke⁺: 0.24%/year (n=38/9088) vs 0.49%/year (n=74/9052), HR=0.51 (95% CI: 0.34, 0.75); other ICH: 0.10%/year

• There were significantly fewer fatal bleeding events vs warfarin. Intracranial: 0.03%/year (n=4/9088) vs 0.20%/year (n=30/9052), HR=0.13 (95% CI: 0.05, 0.37); nonintracranial:

• Concomitant use of drugs affecting hemostasis increases the risk of bleeding, including aspirin and other antiplatelet agents, other anticoagulants,


• Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Discontinue ELIQUIS in patients

• The anticoagulant effect of apixaban can be expected to persist for at least 24 hours after the last dose (i.e., about two half-lives). An agent to reverse the anti-factor Xa activity of apixaban is available. Please visit www.andexxa.com for more information on availability of a reversal agent.



In patients with NVAF, ELIQUIS demonstrated generally consistent results across most major subgroups¹

In ARISTOTLE, results for the primary endpoints were generally consistent across most major subgroups, including:



and 3.1%/year, respectively.

*Scale from 0 to 6 to estimate stroke risk; higher scores predict greater risk.

SELECTED IMPORTANT SAFETY INFORMATION: WARNINGS AND PRECAUTIONS (cont'd)

or spinal hematoma which can result in long-term or permanent paralysis. by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours. potential benefit versus the risk of neuraxial intervention in ELIQUIS patients.

Reference: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY.


Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.

Patients with diabetes who were treated with ELIQUIS bled more than patients without diabetes (3.0%/year vs 1.9%/year, respectively). Major bleeds were observed in patients treated with ELIQUIS and warfarin with diabetes at a rate of 3.0%/year

• Spinal/Epidural Anesthesia or Puncture: Patients treated with ELIQUIS undergoing spinal/epidural anesthesia or puncture may develop an epidural

The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS. The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased

Monitor patients frequently and if neurological compromise is noted, urgent diagnosis and treatment is necessary. Physicians should consider the



EFFICACY

*S(

Refere

In patients with NVAF,

Stroke/SE hazard ratios by baseline characteristics in ARISTOTLE^{1,2}

n of events/N of patients (% per year)

Subgroup	ELIQUIS® (apixaban)	warfarin	Hazard ratio (95% CI)	ELIQUIS better	warfa bett
All patients	212/9120 (1.3)	265/9081 (1.6)	0.79 (0.66, 0.95)		
Prior warfarin/VKA status					
Experienced (57%)	102/5208 (1.1)	138/5193 (1.5)	0.73 (0.57, 0.95)		
Naïve (43%)	110/3912 (1.5)	127/3888 (1.8)	0.86 (0.66, 1.11)		
Age					
<65 years (30%)	51/2731 (1.0)	44/2740 (0.9)	1.16 (0.77, 1.73)	H H	•
≥65 to <75 years (39%)	82/3539 (1.3)	112/3513 (1.7)	0.72 (0.54, 0.96)		
≥75 years (31%)	79/2850 (1.6)	109/2828 (2.2)	0.71 (0.53, 0.95)		
Note: The figure above pres and all of which were presp			\cap	.25 0.5	1
not take into account how		_		ELIQUIS	warfari

factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.


SELECTED IMPORTANT SAFETY INFORMATION: WARNINGS AND PRECAUTIONS (cont'd)

• Spinal/Epidural Anesthesia or Puncture: Patients treated with ELIQUIS undergoing spinal/epidural anesthesia or puncture may develop an epidural or spinal hematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS. The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours. Monitor patients frequently and if neurological compromise is noted, urgent diagnosis and treatment is necessary. Physicians should consider the potential benefit versus the risk of neuraxial intervention in ELIQUIS patients.

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Data on file: APIX 032. Bristol-Myers Squibb Company, Princeton, NJ.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.







Stroke/SE hazar	<mark>d ratios by baseline</mark> n of events/N of pat		in ARISTOTLE ^{1,2}	
Subgroup	ELIQUIS® (apixaban)	warfarin	Hazard ratio (95% CI)	ELIQUIS better
Sex				
Male (65%)	132/5886 (1.2)	160/5899 (1.5)	0.82 (0.65, 1.04)	⊢
Female (35%)	80/3234 (1.3)	105/3182 (1.8)	0.74 (0.56, 1.00)	
Weight				
≤60 kg (11%)	34/1018 (2.0)	52/967 (3.2)	0.63 (0.41, 0.97)	
>60 kg (89%)	177/8070 (1.2)	212/8084 (1.4)	0.83 (0.68, 1.01)	
Prior stroke or transient isc	hemic attack			
Yes (19%)	73/1694 (2.5)	98/1742 (3.2)	0.76 (0.56, 1.03)	⊢
No (81%)	139/7426 (1.0)	167/7339 (1.2)	0.82 (0.65, 1.03)	

factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.

SELECTED IMPORTANT SAFETY INFORMATION: WARNINGS AND PRECAUTIONS (cont'd)

• Spinal/Epidural Anesthesia or Puncture: Patients treated with ELIQUIS undergoing spinal/epidural anesthesia or puncture may develop an epidural or spinal hematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS. The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours. Monitor patients frequently and if neurological compromise is noted, urgent diagnosis and treatment is necessary. Physicians should consider the potential benefit versus the risk of neuraxial intervention in ELIQUIS patients.

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Data on file: APIX 032. Bristol-Myers Squibb Company, Princeton, NJ.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.

S

Refere

better better



- rin

EFFICACY In patients with NVAN Stroke/SE hazar		eding outcomes Subgrou			
	n of events/N of pat	ients (% per year)			
Subgroup	ELIQUIS® (apixaban)	warfarin	Hazard ratio (95% CI)	ELIQUIS better	warfarir better
Diabetes mellitus					
Yes (25%)	57/2284 (1.4)	75/2263 (1.9)	0.75 (0.53, 1.05)	↓↓ ↓	
No (75%)	155/6836 (1.2)	190/6818 (1.5)	0.81 (0.65, 1.00)		_
CHADS ₂ score					
≤1 (34%)	44/3100 (0.7)	51/3083 (0.9)	0.85 (0.57, 1.27)		
2 (36%)	74/3262 (1.2)	82/3254 (1.4)	0.90 (0.66, 1.23)		
	94/2758 (2.0)	132/2744 (2.8)	0.70 (0.54, 0.91)		

factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.



*S(

S

Referen

• Spinal/Epidural Anesthesia or Puncture: Patients treated with ELIQUIS undergoing spinal/epidural anesthesia or puncture may develop an epidural or spinal hematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS. The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours. Monitor patients frequently and if neurological compromise is noted, urgent diagnosis and treatment is necessary. Physicians should consider the potential benefit versus the risk of neuraxial intervention in ELIQUIS patients.

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Data on file: APIX 032. Bristol-Myers Squibb Company, Princeton, NJ.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.



better better

EFFICACY n patients with NVAF, Stroke/SE hazard	Study design Results Ble ratios by baseline n of events/N of pat			
Subgroup	ELIQUIS® (apixaban)	warfarin	Hazard ratio (95% CI)	ELIQUIS better
Creatinine clearance				
<30 mL/min (1%)	6/137 (2.8)	10/133 (5.1)	0.55 (0.20, 1.53)	•
30–50 mL/min (15%)	48/1365 (2.0)	59/1382 (2.5)	0.83 (0.57, 1.21)	
>50–80 mL/min (42%)	87/3817 (1.2)	116/3770 (1.7)	0.74 (0.56, 0.97)	
>80 mL/min (41%)	70/3761 (1.0)	79/3757 (1.1)	0.88 (0.64, 1.21)	
Geographic region				
US (19%)	31/1720 (0.9)	39/1697 (1.2)	0.79 (0.50, 1.27)	• •
Non-US (81%)	181/7400 (1.3)	226/7384 (1.7)	0.79 (0.65, 0.96)	⊢ ● −−−

not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.

SELECTED IMPORTANT SAFETY INFORMATION: WARNINGS AND PRECAUTIONS (cont'd)

• Spinal/Epidural Anesthesia or Puncture: Patients treated with ELIQUIS undergoing spinal/epidural anesthesia or puncture may develop an epidural or spinal hematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS. The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours. Monitor patients frequently and if neurological compromise is noted, urgent diagnosis and treatment is necessary. Physicians should consider the potential benefit versus the risk of neuraxial intervention in ELIQUIS patients.

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Data on file: APIX 032. Bristol-Myers Squibb Company, Princeton, NJ.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.

*S(

Refere



- ELIQUIS warfarin

- - better

better

Stroke/SE hazard	d ratios by baseline		in ARISTOTLE ^{1,2}	
	n of events/N of pa	tients (% per year)		
Subgroup	ELIQUIS® (apixaban)	warfarin	Hazard ratio (95% CI)	ELIQUIS better
Aspirin at randomization				
Yes (31%)	70/2859 (1.3)	94/2773 (1.9)	0.72 (0.53, 0.98)	⊢
No (69%)	142/6261 (1.2)	171/6308 (1.5)	0.83 (0.67, 1.04)	
ELIQUIS dose				
2.5 mg BID (5%)	12/428 (1.7)	22/403 (3.3)	0.50 (0.25, 1.02)	•
5.0 mg BID (95%)	200/8692 (1.3)	243/8678 (1.5)	0.82 (0.68, 0.98)	

not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.



*S

S

Refere

• Spinal/Epidural Anesthesia or Puncture: Patients treated with ELIQUIS undergoing spinal/epidural anesthesia or puncture may develop an epidural or spinal hematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS. The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours. Monitor patients frequently and if neurological compromise is noted, urgent diagnosis and treatment is necessary. Physicians should consider the potential benefit versus the risk of neuraxial intervention in ELIQUIS patients.

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Data on file: APIX 032. Bristol-Myers Squibb Company, Princeton, NJ.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.

ELIQUIS warfarin better better





SAFETY

In patients with NVAF,

Major bleeding hazard ratios by baseline characteristics in ARISTOTLE^{1,2}

n of events/N of patients (% per year)


Subgroup	ELIQUIS® (apixaban)	warfarin	Hazard ratio (95% CI)	ELIQUIS warfa better bette
All patients	327/9088 (2.1)	462/9052 (3.1)	0.69 (0.60, 0.80)	
Prior warfarin/VKA status				
Experienced (57%)	185/5196 (2.1)	274/5180 (3.2)	0.66 (0.55, 0.80)	Here and a second se
Naïve (43%)	142/3892 (2.2)	188/3872 (3.0)	0.73 (0.59, 0.91)	
Age				
<65 years (30%)	56/2732 (1.2)	72/2732 (1.5)	0.78 (0.55, 1.11)	
≥65 to <75 years (39%)	120/3529 (2.0)	166/3501 (2.8)	0.71 (0.56, 0.89)	
≥75 years (31%)	151/2836 (3.3)	224/2819 (5.2)	0.64 (0.52, 0.79)	
Sex				
Male (65%)	225/5868 (2.3)	294/5879 (3.0)	0.76 (0.64, 0.90)	
Female (35%)	102/3220 (1.9)	168/3173 (3.3)	0.58 (0.45, 0.74)	
FLICUUS increases the	risk of bleeding and can	cause serious, potential	ly fatal bleeding	

ELIQUIS Increases the risk of dieeding and can cause serious, potentially fatal, dieeding. Note: The figure above presents effects in various subgroups, all of which are baseline characteristics and all of which were prespecified, if not the groupings. The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Data on file: APIX 032. Bristol-Myers Squibb Company, Princeton, NJ.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.

0.125 0.25 0.5 ELIQUIS warfarin better better



Major Dieeomy n	azard ratios by basel			
Subgroup	n of events/N of pat ELIQUIS [®] (apixaban)	warfarin	Hazard ratio (95% CI)	ELIQUIS better
Weight				
≤60 kg (11%)	36/1013 (2.3)	62/965 (4.3)	0.55 (0.36, 0.83)	
>60 kg (89%)	290/8043 (2.1)	398/8059 (3.0)	0.72 (0.62, 0.83)	H
Prior stroke or transient isch	hemic attack			
Yes (19%)	77/1687 (2.8)	106/1735 (3.9)	0.73 (0.54, 0.98)	
No (81%)	250/7401 (2.0)	356/7317 (2.9)	0.68 (0.58, 0.80)	H
Diabetes mellitus				
Yes (25%)	112/2276 (3.0)	114/2250 (3.1)	0.96 (0.74, 1.25)	
No (75%)	215/6812 (1.9)	348/6802 (3.1)	0.60 (0.51, 0.71)	H

not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Data on file: APIX 032. Bristol-Myers Squibb Company, Princeton, NJ.


Refere.

*S(

S

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.

better better




	n of events/N of pat	ients (% per year)		
Subgroup	ELIQUIS® (apixaban)	warfarin	Hazard ratio (95% CI)	ELIQUIS better
CHADS ₂ score				
≤1 (34%)	76/3093 (1.4)	126/3076 (2.3)	0.59 (0.44, 0.78)	⊢●
2 (36%)	125/3246 (2.3)	163/3246 (3.0)	0.76 (0.60, 0.96)	
≥3 (30%)	126/2749 (2.9)	173/2730 (4.1)	0.70 (0.56, 0.88)	F
Creatinine clearance				
<30 mL/min (1%)	7/136 (3.7)	19/132 (11.9)	0.32 (0.13, 0.78)	
30–50 mL/min (15%)	66/1357 (3.2)	123/1380 (6.0)	0.53 (0.39, 0.71)	
>50–80 mL/min (42%)	157/3807 (2.5)	199/3758 (3.2)	0.76 (0.62, 0.94)	
>80 mL/min (41%)	96/3750 (1.5)	119/3746 (1.8)	0.79 (0.61, 1.04)	

ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding. Note: The figure above presents effects in various subgroups, all of which are baseline characteristics and all of which were prespecified, if not the groupings. The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.

Refere

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Data on file: APIX 032. Bristol-Myers Squibb Company, Princeton, NJ.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.



SAFETY In patients with NVAF, Maior bleeding b	azard ratios by base	line characteristi	ics in ARISTOTI F ¹	.,2	
	n of events/N of pat				
Subgroup	ELIQUIS® (apixaban)	warfarin	Hazard ratio (95% CI)	ELIQUIS better	warfa bett
Aspirin at randomization					
Yes (31%)	129/2846 (2.7)	164/2762 (3.7)	0.75 (0.60, 0.95)		
No (69%)	198/6242 (1.9)	298/6290 (2.8)	0.66 (0.55, 0.79)	H H	
ELIQUIS dose					
2.5 mg BID (5%)	20/424 (3.3)	37/402 (6.7)	0.50 (0.29, 0.86)	► − − − − − − − − − −	
5.0 mg BID (95%)	307/8664 (2.1)	425/8650 (3.0)	0.71 (0.61, 0.82)		

ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding. Note: The figure above presents effects in various subgroups, all of which are baseline characteristics and all of which were prespecified, if not the groupings. The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Data on file: APIX 032. Bristol-Myers Squibb Company, Princeton, NJ.


Refere

*S(

S

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.

0.5 ELIQUIS warfarin better better





CLINICAL TRIALS: ARISTOTLE



Results

In patients with NVAF,

There was generally consistent efficacy and major bleeding events across levels of renal function in ARISTOTLE^{1,2}

RESULTS FROM A PRESPECIFIED SUBGROUP ANALYSIS*

	Efficacy: Stroke/SE	ELIQUIS better	warfarin better	ELIQUIS vs warfarin % per year	ELIQUIS vs w n of even N of patie
	All patients			1.3 vs 1.6	212/9120 vs 26 HR=0.79 (95% Cl:
ICe	<30 mL/min (1%)			2.8 vs 5.1	6/137 vs 10 HR=0.55 (95% CI:
clearar	30-50 mL/min (15%)			2.0 VS 2.5	48/1365 vs 59 HR=0.83 (95% Cl:
Creatinine clearance	>50-80 mL/min (42%)	⊢ − −		1.2 vs 1.7	87/3817 vs 11 HR=0.74 (95% CI:
Cre	>80 mL/min (41%)			1.0 VS 1.1	70/3761 vs 79 HR=0.88 (95% Cl:
	0.	25 0.5 1.	.0 2.	.0	

ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.

- In the ARISTOTLE trial, 5319 patients in the ELIQUIS arm had various levels of renal impairment²

Note: The figures above present effects in one of various subgroups, all of which are baseline characteristics and all of which were prespecified, if not the groupings. The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted. The size of the dot for point estimate (hazard ratio) represents the number of patients across each level of renal function.


*In a prespecified secondary analysis of ARISTOTLE, the outcome of the trial was evaluated in relation to renal function.

SELECTED IMPORTANT SAFETY INFORMATION: WARNINGS AND PRECAUTIONS (cont'd)

in these patients.

References: 1. ELIQUIS® (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Granger CB, Alexander JH, McMurray JJ, et al; for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.



• Patients with a serum creatinine level of >2.5 mg/dL or calculated creatinine clearance of <25 mL/min were excluded from the ARISTOTLE trial²

• Prosthetic Heart Valves: The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves and is not recommended





AVERROES: a phase 3, randomized, double-blind trial vs aspirin in patients with nonvalvular atrial fibrillation (NVAF) who were unsuitable for warfarin^{1,2}

SELECTED IMPORTANT SAFETY INFORMATION: WARNINGS AND PRECAUTIONS (cont'd)

- or who may receive thrombolysis or pulmonary embolectomy.
- Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome (APS): Direct-acting oral anticoagulants (DOACs), [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Connolly SJ, Eikelboom J, Joyner C, et al; for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. *N Engl J Med*. 2011;364(9):806-817.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.

• Acute PE in Hemodynamically Unstable Patients or Patients who Require Thrombolysis or Pulmonary Embolectomy: Initiation of ELIQUIS is not recommended as an alternative to unfractionated heparin for the initial treatment of patients with PE who present with hemodynamic instability

including ELIQUIS, are not recommended for use in patients with triple-positive APS. For patients with APS (especially those who are triple positive








AVERROES was a phase 3, randomized, double-blind trial vs aspirin in over 5500 patients with NVAF who were unsuitable for warfarin¹⁻³

This trial included 5598 patients with NVAF thought not to be candidates for warfarin therapy with 1 or more additional risk factors for stroke.*

Primary objective:

Determine how ELIQUIS 5 mg twice daily (2.5 mg twice daily⁺ in selected patients) compared with aspirin (81 mg to 324 mg once daily) in reducing the risk of stroke or systemic embolism (SE) in patients with NVAF



*Key inclusion criteria: NVAF and >1 additional risk factors for stroke, which included prior stroke or transient ischemic attack, aged >75 years, arterial hypertension (receiving treatment), diabetes mellitus (receiving treatment), heart failure (New York Heart Association Class 2 or higher at the time of enrollment), LVEF $\leq 35\%$, or documented peripheral artery disease. Patients could not be receiving VKA therapy (eg., warfarin), either because it had already been demonstrated to be unsuitable for them or because it was expected to be unsuitable.

LVEF=left ventricular ejection fraction; VKA=vitamin K antagonist. ⁺A dose of 2.5 mg twice daily was assigned to patients with at least 2 of the following characteristics: aged ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. *Intracranial bleeding included intracerebral, intraventricular, subdural, and subarachnoid bleeding. Any type of hemorrhagic stroke was adjudicated and counted as intracranial major bleeding.

SELECTED IMPORTANT SAFETY INFORMATION: ADVERSE REACTIONS

• The most common and most serious adverse reactions reported with ELIQUIS were related to bleeding.

References: 1. ELIQUIS[®] (apixaban) Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Connolly SJ, Eikelboom J, Joyner C, et al; for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817. 3. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(suppl 11):981-992. https://www.nejm.org/doi/suppl/10.1056/NEJMoa1107039/suppl_file/nejmoa1107039_protocol.pdf. Accessed November 11, 2021.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.

Primary efficacy endpoint: stroke/SE **Primary safety endpoint:** major bleeding

Major bleeding was defined as clinically overt bleeding **accompanied by ≥1 of the following:** a decrease in hemoglobin of ≥ 2 g/dL over 24 hours; transfusion of ≥ 2 units of packed red blood cells; bleeding that occurred in at least one of the following critical sites: intracranial,^{*} intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal; and fatal bleeding.

Baseline characteristics: the 2 treatment groups were well balanced with respect to baseline characteristics, including age, stroke risk at entry as measured by a CHADS, score, and prior use of a VKA within 30 days before screening.

BASELINE CHARACTERISTICS

COMMON REASONS FOR WARFARIN UNSUITABILITY


CHADS, SCORE







LV



to be unsuitable for them or because it was expected to be unsuitable.

LVEF=left ventricular ejection fraction; VKA=vitamin K antagonist. ⁺A dose of 2.5 mg twice daily was assigned to patients with at least 2 of the following characteristics: aged ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. *Intracranial bleeding included intracerebral, intraventricular, subdural, and subarachnoid bleeding. Any type of hemorrhagic stroke was adjudicated and counted as intracranial major bleeding.

SELECTED IMPORTANT SAFETY INFORMATION: ADVERSE REACTIONS

• The most common and most serious adverse reactions reported with ELIQUIS were related to bleeding.

References: 1. ELIQUIS[®] (apixaban) Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Connolly SJ, Eikelboom J, Joyner C, et al; for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817. 3. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(suppl 11):981-992. https://www.nejm.org/doi/suppl/10.1056/NEJMoa1107039/suppl_file/nejmoa1107039_protocol.pdf. Accessed November 11, 2021.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.


Studied in AVERROES, a phase 3, randomized, double-blind trial vs aspirin in over

aspirin n=2791		
70±10		
2.1±1.1		
37%	n=1022	
34%	n=954	
29%	n=812	
13%	n=374	
15%	n=426	

Medication doses of aspirin for patients in the aspirin arm of study²

Aspirin dose received at baseline	Number of patient n=2791
81 mg	1786 (64%)
162 mg	750 (27%)
243 mg	60 (2%)
324 mg	184 (7%)
Data not available	11 (<1%)

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Connolly SJ, Eikelboom J, Joyner C, et al; for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817. 3. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817. 3. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817. 3. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817.





Safety

AVERROES wa in over 5500

This trial included 55

Primary objective

Determine how ELI patients) compared risk of stroke or sys



Common reasons for warfarin unsuitability in the AVERROES clinical trial¹

Reason for unsuitability of therapy

Unable/unlikely to obtain INRs at requeste

Patient refused warfarin

CHADS⁺ score of 1 and HCP did not recom

Assessment that INR could not be maintain

Patient could not be relied on to adhere to

Expected difficulty in contacting patient in

HCP=health care provider; INRs=international normalized ratios. *Reasons listed here were reported by 10% of patients or more; reasons reported by less than 10% of patients are not included in this table. ⁺Scale from 0 to 6 to estimate stroke risk; higher scores predict greater risk. **Reference: 1.** Connolly SJ, Eikelboom J, Joyner C, et al; for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817.

*Key inclusion criteria: NVAF and >1 additional risk factors for stroke, which included prior stroke or transient ischemic attack, aged >75 years, arterial hypertension (receiving treatment), diabetes mellitus (receiving treatment), heart failure (New York Heart Association Class 2 or higher at the time of enrollment), LVEF ≤35%, or documented peripheral artery disease. Patients could not be receiving VKA therapy (eg, warfarin), either because it had already been demonstrated to be unsuitable for them or because it was expected to be unsuitable.

LVEF=left ventricular ejection fraction; VKA=vitamin K antagonist. ⁺A dose of 2.5 mg twice daily was assigned to patients with at least 2 of the following characteristics: aged ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. *Intracranial bleeding included intracerebral, intraventricular, subdural, and subarachnoid bleeding. Any type of hemorrhagic stroke was adjudicated and counted as intracranial major bleeding.

SELECTED IMPORTANT SAFETY INFORMATION: ADVERSE REACTIONS

• The most common and most serious adverse reactions reported with ELIQUIS were related to bleeding.

References: 1. ELIQUIS[®] (apixaban) Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Connolly SJ, Eikelboom J, Joyner C, et al; for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817. 3. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(suppl 11):981-992. https://www.nejm.org/doi/suppl/10.1056/NEJMoa1107039/suppl_file/nejmoa1107039_protocol.pdf. Accessed November 11, 2021.


Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.

oy*	ELIQUIS® (apixaban) n=2808	aspirin n=2791
ed intervals	1196 (43%)	1191 (43%)
	1053 (38%)	1039 (37%)
nmend VKA (eg, warfarin)	590 (21%)	605 (22%)
ained in therapeutic range	465 (17%)	468 (17%)
o VKA (eg, warfarin) instruction	437 (16%)	405 (15%)
in case of urgent dose change	322 (11%)	331 (12%)

^r stroke.*

bleeding

were well





AVERROES wa in over 5500

This trial included 5!

Primary objective

Determine how EL patients) compare risk of stroke or sy



CHADS, score¹

A CHADS, score was used to estimate stroke risk in patients with atrial fibrillation. It was calculated by adding up the applicable points below, with higher scores representing a greater risk for stroke.

	CHADS ₂ score		
	Condition	Points	
С	Congestive heart failure	1	
н	Hypertension	1	
Α	Age (≥75)	1	
D	Diabetes mellitus	1	
S	History of stroke or transient ischemic attack	2	
	Possible total:	6 points	

*Key inclusion criter

hypertension (receivir LVEF \leq 35%, or docum to be unsuitable for them of occupie it may expected to be onsolitable.

Reference: 1. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-2870.

LVEF=left ventricular ejection fraction; VKA=vitamin K antagonist. [†]A dose of 2.5 mg twice daily was assigned to patients with at least 2 of the following characteristics: aged ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. *Intracranial bleeding included intracerebral, intraventricular, subdural, and subarachnoid bleeding. Any type of hemorrhagic stroke was adjudicated and counted as intracranial major bleeding.

SELECTED IMPORTANT SAFETY INFORMATION: ADVERSE REACTIONS

• The most common and most serious adverse reactions reported with ELIQUIS were related to bleeding.

References: 1. ELIQUIS[®] (apixaban) Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Connolly SJ, Eikelboom J, Joyner C, et al; for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817. 3. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(suppl 11):981-992. https://www.nejm.org/doi/suppl/10.1056/NEJMoa1107039/suppl_file/nejmoa1107039_protocol.pdf. Accessed November 11, 2021.


Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.

r stroke.*

leeding

were well

arterial me of enrollment), been demonstrated






In patients with NVAF,

Results vs aspirin from the AVERROES clinical trial¹ PRIMARY EFFICACY OUTCOME: ELIQUIS WAS SUPERIOR TO ASPIRIN IN REDUCING THE RISK OF STROKE AND SE



Risk reduction in stroke/SE vs as

HR=0.45 (95% CI: 0.32, 0.62) *P*<0.0001



ARR=absolute risk reduction; CI=confidence interval; HR=hazard ratio; RRR=relative risk reduction.

SELECTED IMPORTANT SAFETY INFORMATION: TEMPORARY INTERRUPTION FOR SURGERY AND OTHER INTERVENTIONS

• ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable adequate hemostasis has been established.

Reference: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.



spiriı	N			
63 113				
irin 791		-		

AVERROES was stopped early on the basis of a prespecified interim analysis showing a significant reduction in stroke/SE for patients taking ELIQUIS compared with patients taking aspirin

or clinically significant bleeding. ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be noncritical in location and easily controlled. Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required. ELIQUIS should be restarted after the surgical or other procedures as soon as






Safety

In patients with NVAF,

Results vs aspirin from the AVERROES clinical trial¹ PRIMARY SAFETY OUTCOME: RATES OF MAJOR BLEEDING EVENTS vs ASPIRIN



ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.

Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.

SELECTED IMPORTANT SAFETY INFORMATION: DRUG INTERACTIONS

taking 2.5 mg twice daily, avoid coadministration of ELIQUIS with combined P-gp and strong CYP3A4 inhibitors. Clarithromycin

Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor, pharmacokinetic data suggest that no dose adjustment is necessary with concomitant administration with ELIQUIS.

carbamazepine, phenytoin, St. John's wort) because such drugs will decrease exposure to apixaban.

Reference: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.

ing events			
Hazard ratio (95% CI)	<i>P</i> value		
1.54 (0.96, 2.45)	0.07		
0.99 (0.23, 4.29)	-		
0.99 (0.39, 2.51)	-		

- In AVERROES, ELIQUIS was associated with an increase in bleeding compared with aspirin that was not statistically significant
- The most common reason for treatment discontinuation in both studies was bleeding-related adverse reactions:
 - In ARISTOTLE, this occurred in 1.7% and 2.5% of patients treated with ELIQUIS and warfarin, respectively
 - In AVERROES, this occurred in 1.5% and 1.3% of patients treated with ELIQUIS and aspirin, respectively


• Combined P-gp and Strong CYP3A4 Inhibitors: Inhibitors of P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) increase exposure to apixaban and increase the risk of bleeding. For patients receiving ELIQUIS doses of 5 mg or 10 mg twice daily, reduce the dose of ELIQUIS by 50% when ELIQUIS is coadministered with drugs that are combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or ritonavir). In patients already

• Combined P-gp and Strong CYP3A4 Inducers: Avoid concomitant use of ELIQUIS with combined P-gp and strong CYP3A4 inducers (e.g., rifampin,





From selected double-blind, randomized, phase 3 trials Summary of primary efficacy and safety endpoints^{1,2}



Major bleeding was defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of ≥ 2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site (intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal), or bleeding with fatal outcome.

*Bleeding events within each subcategory were counted once per subject, but subjects may have contributed events to multiple endpoints. In ARISTOTLE, bleeding events were counted during treatment or within 2 days of stopping study treatment (on-treatment period). ⁺AVERROES was stopped early on the basis of a prespecified interim analysis showing a significant reduction in stroke and SE for ELIQUIS compared with aspirin. [†]In AVERROES, a decrease in hemoglobin of 2 g/dL or more over a 24-hour period.² [§]In ARISTOTLE, intracranial bleed included intracerebral, intraventricular, subdural, and subarachnoid bleeding. Any type of hemorrhagic stroke was adjudicated and counted as an intracranial major bleed.

SELECTED IMPORTANT SAFETY INFORMATION: DRUG INTERACTIONS (cont'd)

the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo.

References: 1. ELIQUIS[®] (apixaban). Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc., New York, NY. 2. Connolly SJ, Eikelboom J, Joyner C, et al; for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.

CY Ipoint	MAJOR BLEEDING EVENTS Primary safety endpoint	ELIQUIS increases the risk of ble cause serious, potentially fatal, l
IN .20)	SUPERIOR BASED ON FEWER MAJOR BLEEDING EVENTS* 2.13%/year (327/9088)	 In ARISTOTLE, superiority to warfarin w attributable to a reduction in hemorrh and ischemic strokes with hemorrhagic compared with warfarin. Purely ischen
o/year farin , 0.95) r ARR	with ELIQUIS vs 3.09%/year (462/9052) with warfarin HR=0.69 (95% CI: 0.60, 0.80) <i>P</i> <0.0001 31% RRR, 0.96%/year ARR	 occurred with similar rates on both drug In AVERROES, ELIQUIS was associated a increase in major bleeding compared with at was not statistically significant (1)
IN) with ear oirin , 0.62) r ARR	NO STATISTICAL DIFFERENCE IN MAJOR BLEEDING EVENTS* 1.41%/year (45/2798) with ELIQUIS vs 0.92%/year (29/2780) with aspirin HR=1.54 (95% CI: 0.96, 2.45) <i>P</i> =0.07 (NS)	 vs 0.92%/year, HR=1.54 [95% CI: 0.96, P=0.07) The most common reason for treatmediscontinuation in ARISTOTLE and AVE bleeding-related adverse reactions; in this occurred in 1.7% and 2.5% of patient with ELIQUIS and warfarin, respectively AVERROES, in 1.5% and 1.3% on ELIQU aspirin, respectively

• Anticoagulants and Antiplatelet Agents: Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk post-acute coronary syndrome patients treated with aspirin or

eding and can bleeding.

was primarily nagic stroke ic conversion nic strokes Ugs

with an with aspirin ..41%/year 2.45];

ent RROES was ARISTOTLE, ients treated ly, and in UIS and



IMPORTANT SAFETY INFORMATION

WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA

(A) Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant. (B) Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

- use of indwelling epidural catheters
- a history of traumatic or repeated epidural or spinal punctures
- a history of spinal deformity or spinal surgery
- optimal timing between the administration of ELIQUIS and neuraxial procedures is not known

Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated.

CONTRAINDICATIONS

- Active pathological bleeding
- Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions)

WARNINGS AND PRECAUTIONS

- transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.
- Bleeding Risk: ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.
 - heparin, thrombolytic agents, SSRIs, SNRIs, and NSAIDs.
 - with active pathological hemorrhage.
- or spinal hematoma which can result in long-term or permanent paralysis. by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours. potential benefit versus the risk of neuraxial intervention in ELIQUIS patients.

• concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants

• Increased Risk of Thrombotic Events after Premature Discontinuation: Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the

• Concomitant use of drugs affecting hemostasis increases the risk of bleeding, including aspirin and other antiplatelet agents, other anticoagulants,

• Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Discontinue ELIQUIS in patients

• The anticoagulant effect of apixaban can be expected to persist for at least 24 hours after the last dose (i.e., about two half-lives). An agent to reverse the anti-factor Xa activity of apixaban is available. Please visit www.andexxa.com for more information on availability of a reversal agent. • Spinal/Epidural Anesthesia or Puncture: Patients treated with ELIQUIS undergoing spinal/epidural anesthesia or puncture may develop an epidural

The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS. The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased

Monitor patients frequently and if neurological compromise is noted, urgent diagnosis and treatment is necessary. Physicians should consider the

(continued on next page)





IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

- in these patients.
- or who may receive thrombolysis or pulmonary embolectomy.
- Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome (APS): Direct-acting oral anticoagulants (DOACs), [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.

ADVERSE REACTIONS

• The most common and most serious adverse reactions reported with ELIQUIS were related to bleeding.

TEMPORARY INTERRUPTION FOR SURGERY AND OTHER INTERVENTIONS

• ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable adequate hemostasis has been established.

DRUG INTERACTIONS

taking 2.5 mg twice daily, avoid coadministration of ELIQUIS with combined P-gp and strong CYP3A4 inhibitors. Clarithromycin

Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor, pharmacokinetic data suggest that no dose adjustment is necessary with concomitant administration with ELIQUIS.

- carbamazepine, phenytoin, St. John's wort) because such drugs will decrease exposure to apixaban.
- the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo.

PREGNANCY

- adverse developmental outcomes. Treatment may increase the risk of bleeding during pregnancy and delivery, and in the fetus and neonate.
 - Labor or delivery: ELIQUIS use during labor or delivery in women who are receiving neuraxial anesthesia may result in epidural or spinal hematomas. Consider use of a shorter acting anticoagulant as delivery approaches.

• Prosthetic Heart Valves: The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves and is not recommended

• Acute PE in Hemodynamically Unstable Patients or Patients who Require Thrombolysis or Pulmonary Embolectomy: Initiation of ELIQUIS is not recommended as an alternative to unfractionated heparin for the initial treatment of patients with PE who present with hemodynamic instability

including ELIQUIS, are not recommended for use in patients with triple-positive APS. For patients with APS (especially those who are triple positive

or clinically significant bleeding. ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be noncritical in location and easily controlled. Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required. ELIQUIS should be restarted after the surgical or other procedures as soon as

• Combined P-gp and Strong CYP3A4 Inhibitors: Inhibitors of P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) increase exposure to apixaban and increase the risk of bleeding. For patients receiving ELIQUIS doses of 5 mg or 10 mg twice daily, reduce the dose of ELIQUIS by 50% when ELIQUIS is coadministered with drugs that are combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or ritonavir). In patients already

• Combined P-gp and Strong CYP3A4 Inducers: Avoid concomitant use of ELIQUIS with combined P-gp and strong CYP3A4 inducers (e.g., rifampin,

• Anticoagulants and Antiplatelet Agents: Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk post-acute coronary syndrome patients treated with aspirin or

• The limited available data on ELIQUIS use in pregnant women are insufficient to inform drug-associated risks of major birth defects, miscarriage, or

(continued on next page)



IMPORTANT SAFETY INFORMATION (cont'd)

LACTATION

• Breastfeeding is not recommended during treatment with ELIQUIS.

FEMALES AND MALES OF REPRODUCTIVE POTENTIAL

uterine bleeding, potentially requiring gynecological surgical interventions, identified with oral anticoagulants including ELIQUIS should be assessed in these patients and those with abnormal uterine bleeding.

Please see Important Safety Information throughout and Full Prescribing Information, including Boxed WARNINGS, or visit ELIQUIS.com.

ELIQUIS[®] and the ELIQUIS logo are trademarks of Bristol-Myers Squibb Company. © 2021 Bristol-Myers Squibb Company. 432-US-2101632 12/21

• Females of reproductive potential requiring anticoagulation should discuss pregnancy planning with their physician. The risk of clinically significant

